Shares of Curis are soaring after the United States Patent and Trademark Office posted yesterday a patent for the company regarding phosphoinositide 3-kinase inhibitors with a zinc binding moiety. The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer, the agency said. Shares of Curis are up 64%, or 78c, to $2.00 in premarket trading. The stock closed Tuesday up 42% to $1.22.